On Sept. 14, 2020, Humanigen and Lonza announced a strategic collaboration to expand the manufacturing capacity for lenzilumab in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.

Production of lenzilumab was to scheduled to begin at Lonza’s 2,000L manufacturing facilities at Hayward (CA). Technology transfer was expected to begin in Q3 2020.